Pre-made Camidanlumab Tesirine benchmark antibody (Whole mAb ADC, anti-IL2RA therapeutic antibody, Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Camidanlumab Tesirine benchmark antibody (Whole mAb ADC, anti-IL2RA therapeutic antibody, Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Camidanlumab tesirine (Cami-T or ADCT-31) is an antibody-drug conjugate (ADC) composed of a human antibody that binds to the protein CD25, conjugated to a pyrrolobenzodiazepine dimer toxin. The experimental drug, developed by ADC Therapeutics is being tested in clinical trials for the treatment of B-cell Hodgkin's lymphoma (HL) and non-Hodgkin lymphoma (NHL), and for the treatment of B-cell acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-768-1mg	1mg	Inquiry
GMP-Bios-INN-768-10mg	10mg	Inquiry
GMP-Bios-INN-768-100mg	100mg	Inquiry
GMP-Bios-INN-768-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Camidanlumab Tesirine Biosimilar, Whole Mab Adc, Anti-Il2Ra Antibody: Anti-CD25/IDDM10/IL2R/IMD41/TCGFR/p55 therapeutic antibody Drug Conjugate
INN Name	Camidanlumab Tesirine
Target	IL2RA
Format	Whole mAb ADC
Derivation	human
Species Reactivity	human
CH1 Isotype	IgG1 - kappa
VD LC	IgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Genmab A/S (Copenhagen Denmark) / ADC Therapeutics (Epalinges Switzerland)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0